Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Galapagos NV ADR GEN DE WITTELAAN L11 A3 MECHELEN C9 2800 BEL

www.glpg.com Employees: 1,123 P: 321-534-2900 F: +32 15342901

Description:

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.

Key Statistics

Overview:

Market Capitalization, $K 1,763,404
Enterprise Value, $K 1,582,874
Shares Outstanding, K 65,897
Annual Sales, $ 259,450 K
Annual Net Income, $ 229,120 K
Last Quarter Sales, $ 67,780 K
Last Quarter Net Income, $ 97,950 K
EBIT, $ -12,390 K
EBITDA, $ 34,840 K
60-Month Beta 0.23
% of Insider Shareholders 2.91%
% of Institutional Shareholders 32.46%
Float, K 63,979
% Float 97.09%
Short Volume Ratio 0.67

Growth:

1-Year Return -32.31%
3-Year Return -52.16%
5-Year Return -87.22%
5-Year Revenue Growth -30.88%
5-Year Earnings Growth 89.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.39 on 05/02/24
Next Earnings Date 10/30/24
Earnings Per Share ttm 1.33
EPS Growth vs. Prev Year -9.30%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GLPG Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 61.38
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 88.31%
Debt/Equity 0.00
Price/Sales 6.80
Price/Cash Flow 41.10
Price/Book 0.56
Book Value/Share 47.76
Interest Coverage 3.15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar